BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6503978)

  • 41. [Endoscopic administration of OK-432 in gastric cancer].
    Inbe A; Sumii K; Haruma K; Uemura N; Tari A; Yoshihara M; Tokutomi T; Inaba Y; Sekito M; Ogoshi H
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):514-9. PubMed ID: 3954375
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of large dose intratumoral administration of OK-432 in advanced cancer patients.
    Sakamoto J; Kondo T; Kamei H; Ichihashi H; Yamamura Y
    Nagoya J Med Sci; 1979 Dec; 42(1-2):27-36. PubMed ID: 530302
    [No Abstract]   [Full Text] [Related]  

  • 43. Role of urokinase-type plasminogen activator in local immunotherapy.
    Takeda T; Ito Y; Wakasugi E; Kobayashi T; Monden M
    Oncol Rep; 1998; 5(2):329-33. PubMed ID: 9468551
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanism of induction of endogenous tumor necrosis factor in ascites of ovarian cancer patients by OK-432, a streptococcal preparation.
    Mori H; Itoh N; Tamaya T
    Immunopharmacol Immunotoxicol; 1989; 11(1):33-53. PubMed ID: 2503555
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adoptive immunotherapy in tumor-bearing mice with OK-432-induced killer cells.
    Ujiie T
    Jpn J Exp Med; 1988 Apr; 58(2):109-14. PubMed ID: 3261814
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effects of OK-432 intraportal administration on cell-mediated immune responses].
    Minamimura T; Katsuyama S; Yamasaki K; Ookami H; Okamoto M; Masuyama K; Yamamoto K; Takemori S; Arai H; Sakamoto T; Tazawa K; Fujimaki M
    Gan To Kagaku Ryoho; 1997 Sep; 24(12):1867-9. PubMed ID: 9382553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic effect of OK-432 induced endogenous TNF on tumor bearing mice and cancer patients.
    Watanabe N; Niitsu Y; Yamauchi N; Neda H; Sone H; Urushizaki I; Yamamoto A; Nagamuta M; Sugawara Y
    Immunopharmacol Immunotoxicol; 1988; 10(1):53-65. PubMed ID: 3361071
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Role of the spleen in OK-432 immunotherapy and characterization of effector cells].
    Yamagishi H; Naito K; Maeda Y; Kobayashi M; Kurioka H; Fujimori C; Tanaka T; Hashimoto I
    Gan To Kagaku Ryoho; 1983 Jul; 10(7):1670-8. PubMed ID: 6870309
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Combination therapy of large amount of carboquone and OK-432 for unresectable lung cancer].
    Nakarai I; Honda T; Jinnai S; Kita T; Shinoda A
    Gan To Kagaku Ryoho; 1982 Jul; 9(6):1006-11. PubMed ID: 7184436
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Changes in cytokine levels in ascitic fluid after intraperitoneal administration of OK-432].
    Terashima M; Takagane A; Abe K; Kuboi M; Asahi H; Saito K
    Gan To Kagaku Ryoho; 1993 Aug; 20(11):1443-5. PubMed ID: 8373202
    [TBL] [Abstract][Full Text] [Related]  

  • 51. OK-432 stimulates primary production and activity of murine natural killer cells.
    Pollack SB
    Nat Immun Cell Growth Regul; 1987; 6(5):224-36. PubMed ID: 3444437
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Local immunotherapy with streptococcal preparation, OK-432 in superficial bladder tumors, and common antigens between OK-432 and the tumor].
    Fujioka T; Shiraishi M; Tanji S; Koike H; Suzuki K; Kumagai K; Aoki H; Sakuma Y; Ohhori T; Kubo T
    Hinyokika Kiyo; 1989 Feb; 35(2):253-7. PubMed ID: 2735236
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Clinical investigation of intratumoral OK-432 administration].
    Shimada K; Tabuse K; Kono N; Katsumi M; Yamamoto H; Yamamoto Y; Endo A
    Gan To Kagaku Ryoho; 1983 Aug; 10(8):1844-9. PubMed ID: 6882008
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [NK activities in cancer patients--their modification by an immunopotentiator].
    Sasanami T; Fujishima A; Moriya Y; Imai K; Yachi A
    Gan To Kagaku Ryoho; 1982 Dec; 9(12):2186-92. PubMed ID: 7184392
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of OK-432 on the lymphnode metastasis of MCA-sarcoma cell lines: a new therapeutic approach.
    Inoh A; Kodama Y; Yokoro K
    Hiroshima J Med Sci; 1989 Dec; 38(4):213-9. PubMed ID: 2637250
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Intratumoral injection of OK-432 in conjunction with fibrinogen greatly enhances antitumor effect on colorectal carcinomas].
    Monden T; Morimoto H; Murotani M; Yagyu T; Nagaoka H; Shimano T; Mori T
    Nihon Geka Gakkai Zasshi; 1991 Jan; 92(1):31-6. PubMed ID: 1707498
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of a streptococcal preparation, OK-432, on hematopoietic spleen colony formation in irradiated mice.
    Hiraoka A; Yamagishi M; Ohkubo T; Kamamoto T; Yoshida Y; Uchino H
    Cancer Res; 1981 Jul; 41(7):2954-8. PubMed ID: 7018674
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Anticancer effects of OK-432 (2). Anticancer actions of M phi activated by OK-432].
    Saito M; Aonuma E; Noda T; Nakadate I; Nanjo M; Ebina T; Ishida N
    Gan To Kagaku Ryoho; 1983 May; 10(5):1363-71. PubMed ID: 6870302
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Correlation between anti-tumor effect and delayed hypersensitivity induced by topically applied OK-432 with histological findings].
    Kokunai I; Mori T; Yayoi E; Matuura N; Kosaki G
    Nihon Geka Gakkai Zasshi; 1985 Mar; 86(3):258-65. PubMed ID: 3982380
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Antitumor effect of OK-432 (1)--antitumor effect of OK-432 induced interferon-gamma (IFN gamma)].
    Saito M; Yamaguchi T; Aonuma E; Noda T; Edina T; Ishida N
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):2031-7. PubMed ID: 6820888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.